Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: Insulet | History Defined

Are Wall Street Analysts Bullish on Insulet Stock?

Although Insulet has lagged the broader market over the past year, Wall Street analysts remain strongly optimistic about the company’s long-term growth prospects.

Barchart

Is Insulet Stock Underperforming the Dow?

Insulet has underperformed the Dow recently, yet analysts remain highly optimistic about the stock’s prospects.

Barchart

What Are Wall Street Analysts' Target Price for Insulet Stock?

Insulet has underperformed the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

What You Need To Know Ahead of Insulet’s Earnings Release

Here’s what analysts are expecting from the underperforming stock Insulet prior to its Q4 earnings.

Barchart

Is Insulet Stock Underperforming the Nasdaq?

Although Insulet has underperformed the Nasdaq recently, analysts remain highly optimistic about the stock’s prospects.

Barchart

Insulet Stock: Is Wall Street Bullish or Bearish?

Insulet has outperformed the broader market over the past year, and analysts remain strongly bullish on the company’s trajectory.

Barchart

Is Insulet Stock Outperforming the S&P 500?

Insulet has outperformed the S&P 500 over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Insulet Stock: Analyst Estimates & Ratings

Insulet has significantly outpaced the broader market over the past year, and analysts remain very bullish on the stock’s prospects.

Barchart

Cisco, Rocket Companies, Insulet And More On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, said he remains long on Rocket Companies, Inc. (NYSE:RKT).

Benzinga

Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5

Insulet Corporation (NASDAQ:PODD) reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents.

Benzinga

How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?

Insulet has outperformed the Medical Devices industry over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

3 Medical Technology Stocks Outperforming in 2025

Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns.

MarketBeat

Do Wall Street Analysts Like Insulet Stock?

Insulet has significantly outpaced the broader market over the past year, and analysts remain bullish on the stock’s prospects.

Barchart

Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer

Insulet's earnings and upgraded guidance recently propelled its stock to S&P 500 leadership, showcasing strong execution in the diabetes care market.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Here's What to Expect From Insulet's Next Earnings Report

Insulet is set to release its first-quarter results next month, and analysts expect a double-digit earnings growth.

Barchart

Insulet Stock: Is PODD Outperforming the Healthcare Sector?

As Insulet has outperformed relative to the healthcare sector over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Insulet Stock Outlook: Is Wall Street Bullish or Bearish?

Insulet has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

Earnings Preview: What to Expect From Insulet's Report

Insulet is scheduled to release its fiscal fourth-quarter earnings next month, and analysts project a double-digit profit decline.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Insulet Stock Outperforming the Dow?

Insulet has outperformed the Dow recently, and analysts remain strongly optimistic about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Insulet Stock Will Climb or Sink?

As Insulet outperformed relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

International Business Times

Dexcom Glucose Data To Be Integrated With ŌURA Rings

Dexcom and ŌURA have partnered to integrate Dexcom's glucose biosensing feature with the ŌURA Ring's health metrics to help improve consumers' metabolic health.

The Conversation

Glucose monitors for diabetes have finally been funded – but a chronic workforce shortage will limit the benefits

Pharmac’s decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live with type 1 diabetes in Aotearoa New Zealand is good news.

Barchart

Is Insulet Stock Outperforming the Nasdaq?

Insulet has outperformed the Nasdaq Composite over the past year and analysts remain strongly bullish about the stock’s prospects.

Barchart

Stocks Close in the Red, Nvidia Trades Lower After Earnings Report

The Nasdaq 100 fell to a 2-week low on Wednesday, dragging down the broader market. Nvidia stock drops after the AI company released its earnings report.

Barchart

Stocks Close Lower, Nvidia Trades Lower After Earnings Report

The Nasdaq 100 fell to a 2-week low on Wednesday, dragging down the broader market. Nvidia stock drops after the AI company released its earnings report.

1 2 3

People

Joshua Brown

38 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Ritholtz Wealth Management

29 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.